{"id":150378,"date":"2010-01-07T15:32:57","date_gmt":"2010-01-07T20:32:57","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=57603"},"modified":"2010-01-07T15:32:57","modified_gmt":"2010-01-07T20:32:57","slug":"agreement-between-genzyme-and-san-diego-activist-shareholder-suggests-truce","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/150378","title":{"rendered":"Agreement Between Genzyme and San Diego Activist Shareholder Suggests Truce"},"content":{"rendered":"\n<div style=\"text-transform:uppercase\"><a href=\"http:\/\/www.xconomy.com\/tag\/Life-Sciences\/\">Life Sciences<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/proxy-battle\/\">Proxy Battle<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/people\/\">people<\/a><\/div>\n<p>\t\t<a rel=\"attachment wp-att-42847\" href=\"http:\/\/www.xconomy.com\/boston\/2009\/09\/23\/genzyme-says-supplies-sales-of-two-enzyme-drugs-will-be-even-lower-than-previously-predicted\/attachment\/genzyme\/\"><img loading=\"lazy\" decoding=\"async\" style=\"float:right;margin: 0px 0 5px 15px;\" class=\"alignnone size-full wp-image-42847\" title=\"Genzyme Logo New\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/images\/2009\/09\/genzyme.png\" alt=\"Genzyme Logo New\" width=\"152\" height=\"49\" \/><\/a><br \/>\n\t\t<strong>Bruce V. Bigelow wrote:<\/strong><\/p>\n<p>In what may be a pre-emptive move to turn down the heat, beleaguered Genzyme (NASDAQ: <a href=\"http:\/\/finance.yahoo.com\/q?s=GENZ\">GENZ<\/a>) says today it has entered into a &#8220;mutual cooperation agreement&#8221; with Relational Investors, the $6 billion activist investment fund based in San Diego.<\/p>\n<p>The private investment firm began to acquire Genzyme shares in 2008, and Relational co-founder Ralph Whitworth began to publicly call for changes late last year at the Cambridge, MA-based biotech. Whitworth&#8217;s expertise in corporate governance and his reputation as an activist investor triggered a flurry of media speculation about the prospects for a shakeup at Genzyme. The San Diego fund now owns about 4 percent of the company&#8217;s stock.<\/p>\n<p>Whitworth praised Genzyme&#8217;s appointment of former Schering-Plough executive Robert J. Bertolini to its board in early December, but called for &#8220;significant further improvements&#8221; in the composition of Genzyme&#8217;s board. At the time, Whitworth would not rule out waging a proxy battle to bring about such changes, according to <a href=\"http:\/\/online.wsj.com\/article\/BT-CO-20091209-710718.html\">a Dow Jones report<\/a>. (Whitworth&#8217;s office did not respond in December to my request for an interview.)<\/p>\n<p>Whitworth, who joined investor David Batchelder at Relational Investors in the early 1990s, prefers to work for change inside the boardroom. In <a href=\"http:\/\/www.rillc.com\/team_principals.htm\">his profile<\/a> on the Relational Investors website, Whitworth describes the time he served as chairman of Waste Management in 1999 &#8220;as a major crisis management assignment in the midst of an accounting scandal.&#8221; Whitworth, who served on Waste Management&#8217;s board from 1998 to 2004, assumed responsibility for overall management at the company in 1999, including an extensive audit and a recruiting effort to replace the management team. In 2000, during Whitworth&#8217;s tenure as chairman at Apria Healthcare Group, Institutional Shareholder Services named the home health provider the &#8220;best governed company in North America.&#8221; At the same time, Whitworth&#8217;s not afraid to get into a public scrap&#8212;such as the 2007 battle that Relational Investors waged over the compensation package awarded to Home Depot CEO Robert Nardelli.<\/p>\n<p>As part of the agreement announced today, Relational Investors has pledged to support Genzyme&#8217;s slate of board candidates and other proposals in 2010. If Relational is not satisfied with those changes and still wants a <span class=\"read_more\"> <a href=\"http:\/\/www.xconomy.com\/san-diego\/2010\/01\/07\/agreement-between-genzyme-and-san-diego-activist-shareholder-suggests-truce\/2\/\"> &#8230;Next Page &raquo;<\/a><\/span><\/p>\n<div class=\"postFooter\"><a href=\"http:\/\/www.xconomy.com\/san-diego\/2010\/01\/07\/agreement-between-genzyme-and-san-diego-activist-shareholder-suggests-truce\/#comments\">Comments<\/a> | <a href=http:\/\/www.xconomy.com\/reprints\/>Reprints<\/a> | Share: &nbsp;<br \/>\n<a href=\"http:\/\/twitter.com\/home?status=RT%20@Xconomy%20Agreement%20Between%20Genzyme%20and%20San%20Diego%20Activist%20Shareholder%20Suggests%20Truce%20http:\/\/xconomy.com\/?p=57603\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/twitter.gif\" alt=\"Retweet\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.xconomy.com\/san-diego\/2010\/01\/07\/agreement-between-genzyme-and-san-diego-activist-shareholder-suggests-truce\/&#038;t=Agreement%20Between%20Genzyme%20and%20San%20Diego%20Activist%20Shareholder%20Suggests%20Truce\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/facebook.gif\" alt=\"Facebook\"\/><\/a><br \/>\n&nbsp;<a href=http:\/\/www.xconomy.com\/san-diego\/2010\/01\/07\/agreement-between-genzyme-and-san-diego-activist-shareholder-suggests-truce\/email\/  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/email.gif\" alt=\"Email\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/sharethis.com\/item?publisher=bfda184d-6684-4f7a-a23f-ca4ed4db9287&amp;title=Agreement+Between+Genzyme+and+San+Diego+Activist+Shareholder+Suggests+Truce&amp;url=http%3A%2F%2Fwww.xconomy.com%2Fsan-diego%2F2010%2F01%2F07%2Fagreement-between-genzyme-and-san-diego-activist-shareholder-suggests-truce%2F\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/share.gif\" alt=\"Share\"\/><\/a>\n<\/div>\n<p>\t     \t\t<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<a href=\"http:\/\/ads.pheedo.com\/click.phdo?s=10b218f8deb4f0c75e7f46024c54a37b&#038;p=1\"><img decoding=\"async\" alt=\"\" style=\"border: 0;\" border=\"0\" src=\"http:\/\/ads.pheedo.com\/img.phdo?s=10b218f8deb4f0c75e7f46024c54a37b&#038;p=1\"\/><\/a><br \/>\n<img loading=\"lazy\" decoding=\"async\" alt=\"\" height=\"0\" width=\"0\" border=\"0\" style=\"display:none\" src=\"http:\/\/a.rfihub.com\/eus.gif?eui=2218\"\/><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/I8eRB08jT_BZU9XFbDd6jnqCBEQ\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/I8eRB08jT_BZU9XFbDd6jnqCBEQ\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/I8eRB08jT_BZU9XFbDd6jnqCBEQ\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/I8eRB08jT_BZU9XFbDd6jnqCBEQ\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Xconomy_Full\/~4\/WMdyJ18xa2E\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Life Sciences, Proxy Battle, people Bruce V. Bigelow wrote: In what may be a pre-emptive move to turn down the heat, beleaguered Genzyme (NASDAQ: GENZ) says today it has entered into a &#8220;mutual cooperation agreement&#8221; with Relational Investors, the $6 billion activist investment fund based in San Diego. The private investment firm began to acquire [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-150378","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/150378","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=150378"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/150378\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=150378"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=150378"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=150378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}